Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP.

Blood. 2006 Oct 1;108(7):2173-81. Epub 2006 Jun 1.

3.

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A, Reinecke P, Germing U, Skoda RC.

Haematologica. 2008 Jan;93(1):34-40. doi: 10.3324/haematol.11581.

4.

Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.

Tatic A, Vasilică M, Coliţă A, Vasilache D, Dobrea C, Jardan C, Găman AM, Crişan AM, Coliţă D, Coriu D.

Rom J Morphol Embryol. 2013;54(4):1177-82.

5.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

6.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
7.

Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.

Horn T, Kremer M, Dechow T, Pfeifer WM, Geist B, Perker M, Duyster J, Quintanilla-Martinez L, Fend F.

J Mol Diagn. 2006 Jul;8(3):299-304.

8.

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.

Jekarl DW, Han SB, Kim M, Lim J, Oh EJ, Kim Y, Kim HJ, Min WS, Han K.

Korean J Hematol. 2010 Mar;45(1):46-50. doi: 10.5045/kjh.2010.45.1.46. Epub 2010 Mar 31.

9.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

10.

High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.

Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F, Criel A, Selleslag D.

Blood. 2007 Feb 1;109(3):1334-5. No abstract available.

11.

Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.

Gurevich I, Luthra R, Konoplev SN, Yin CC, Medeiros LJ, Lin P.

Am J Clin Pathol. 2011 Mar;135(3):398-403. doi: 10.1309/AJCPT0B6VEQPRCOA.

PMID:
21350094
12.

Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.

Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S.

Leukemia. 2008 Jun;22(6):1295-8. Epub 2007 Dec 6. No abstract available.

PMID:
18059483
13.

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.

Wang SA, Hasserjian RP, Loew JM, Sechman EV, Jones D, Hao S, Liu Q, Zhao W, Mehdi M, Galili N, Woda B, Raza A.

Leukemia. 2006 Sep;20(9):1641-4. Epub 2006 Jul 27. No abstract available.

PMID:
16871284
14.

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A.

Blood. 2005 Aug 15;106(4):1207-9. Epub 2005 Apr 28.

15.

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Gallì A, Travaglino E, Brisci A, Rumi E, Passamonti F, Invernizzi R, Cremonesi L, Boultwood J, Wainscoat JS, Hellström-Lindberg E, Cazzola M.

Blood. 2009 Oct 22;114(17):3538-45. doi: 10.1182/blood-2009-05-222331. Epub 2009 Aug 19.

16.

Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.

Ho CL, Wu YY, Hung HM, Chang PY, Kao WY, Chen YC, Chao TY.

J Formos Med Assoc. 2012 Jan;111(1):34-40. doi: 10.1016/j.jfma.2012.01.003. Epub 2012 Feb 1.

17.

JAK2 in myeloproliferative disorders is not just another kinase.

Tefferi A, Gilliland DG.

Cell Cycle. 2005 Aug;4(8):1053-6. Epub 2005 Aug 26.

PMID:
15970705
18.

The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.

Lucia E, Martino B, Mammi C, Vigna E, Mazzone C, Gentile M, Qualtieri G, Bisconte MG, Naccarato M, Gentile C, Laganà C, Romeo F, Neri A, Nobile F, Morabito F.

Leuk Lymphoma. 2008 Oct;49(10):1907-15. doi: 10.1080/10428190802290652.

PMID:
18720212
19.

Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.

Ayad MW, Nafea D.

Genet Test Mol Biomarkers. 2011 Jan-Feb;15(1-2):17-21. doi: 10.1089/gtmb.2010.0093. Epub 2010 Oct 29.

PMID:
21034166
20.

Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.

Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED.

Am J Surg Pathol. 2007 Feb;31(2):233-9.

PMID:
17255768

Supplemental Content

Support Center